42 research outputs found
Supplementary Figure 10 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 10 shows the IHC markers tested in MNA and NMNA NB PDXs.</p
Supplementary Figure 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 2 demonstrates an increase of sub-G1 fragments upon elimusertib treatment as measured using FACS.</p
Supplementary Table 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 2 lists characteristics of PDX origin.</p
Supplementary Figure 12 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 12 shows changes in pHH3, yH2AX and Clc3 expression in PDXs of different entities.</p
Supplementary Table 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 1 shows AUC and IC50 values for all pediatric cancer cell lines tested.</p
Supplementary Figure 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 6 displays the body weight curves of all PDX-bearing mice over the course of treatment.</p
Supplementary Figure 13 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 13 depicts the correlation of baseline IHC marker expression to treatment response.</p
Supplementary Figure 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 7 depicts the overall survival of each pediatric cancer entity under elimusertib treatment.</p
Supplementary Table 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Table 3 shows statistics for all tumor volume curves.</p
Supplementary Figure 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models
Supplementary Figure 4 shows immunofluorescence stainings of R-loops and their quanitfication in pediatric cancer cell lines.</p